Related Experiment Video

Updated: Jan 11, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.3K

Precision Oncology in Pancreatic Cancer and Future Treatment Directions

Layal Al Mahmasani1, Eileen M O'Reilly2

  • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, Office 104, New York, NY 10065, USA.

Surgical Oncology Clinics of North America
|November 13, 2025
PubMed

Insights

Pancreatic cancer (PDAC) treatment is evolving beyond chemotherapy. This review highlights approved and emerging targeted therapies, focusing on key targets like KRAS, to improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy.
  • Current treatment for metastatic PDAC relies heavily on cytotoxic chemotherapy.
  • Advances in molecular profiling are driving the development of targeted therapies.

Purpose of the Study:

  • To provide an overview of current FDA-approved or guideline-endorsed targeted therapies for PDAC.
  • To summarize emerging targeted therapies with potential to improve PDAC patient outcomes.
  • To discuss key emerging targets in PDAC, including KRAS, claudin, and MTAP.

Main Methods:

  • Literature review of FDA-approved and guideline-endorsed targeted therapies for PDAC.
  • Summary of preclinical and clinical data for emerging targeted therapies.
  • Analysis of major molecular targets in PDAC.

Main Results:

  • A limited number of targeted therapies are currently approved for PDAC.
  • Several novel targeted therapies targeting KRAS, claudin, MTAP, and other pathways are under investigation.
  • These emerging therapies show promise for improving survival and treatment efficacy.

Conclusions:

  • Targeted therapies represent a significant advancement in PDAC treatment.
  • Further research and clinical trials are crucial to realize the full potential of emerging therapies.
  • Precision oncology approaches are key to advancing PDAC patient care.
Keywords:
Clinical trialsMolecular alterationsPancreatic cancerPrecision medicineTargeted therapy

More Related Videos

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

3.7K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K